We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

184 hedge funds and large institutions have $761M invested in Acorda Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 79 increasing their positions, 41 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 41

24% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 21

3% more funds holding

Funds holding: 179 → 184 (+5)

8% less capital invested

Capital invested by funds: $826M → $761M (-$65M)

52% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $5.05M

Holders
184
Holders Change
+5
Holders Change %
+2.79%
% of All Funds
3.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
79
Reduced
41
Closed
21
Calls
$2.4M
Puts
$5.05M
Net Calls
-$2.65M
Net Calls Change
-$26M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$27.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$11.5M
3
State Street
State Street
Massachusetts
+$9.6M
4
Prudential Financial
Prudential Financial
New Jersey
+$6.06M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$5.08M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$17.3M
2
Invesco
Invesco
Georgia
-$17.1M
3
SCM
Scopia Capital Management
New York
-$15.5M
4
Millennium Management
Millennium Management
New York
-$11M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nisa Investment Advisors
176
Nisa Investment Advisors
Missouri
$4K – – –
Daiwa Securities Group
177
Daiwa Securities Group
Japan
$3K – – –
GWMIA
178
Global Wealth Management Investment Advisory
Florida
$3K +$3.6K +2 New
Walleye Trading
179
Walleye Trading
New York
$3K +$3.6K +2 New
WAM
180
Wealthspire Advisors (Maryland)
Maryland
$2K +$1.8K +1 New
GT
181
Glenmede Trust
Pennsylvania
$1.9K +$3.6K +2 +0.2%
CAM
182
Cresset Asset Management
Illinois
$1K – – –
IAS
183
IMA Advisory Services
Colorado
$1K – – –
PCG
184
Private Capital Group
Connecticut
$1K – – –
HGWM
185
Harvest Group Wealth Management
Massachusetts
$1K +$1.8K +1 New
PHS
186
PFM Health Sciences
California
– -$17.3M -9,239 Closed
MCM
187
Matarin Capital Management
New York
– -$2.12M -1,134 Closed
OTPPB
188
Ontario Teachers' Pension Plan Board
Ontario, Canada
– -$1.21M -647 Closed
TI
189
Trexquant Investment
Connecticut
– -$747K -400 Closed
PP
190
PDT Partners
New York
– -$649K -347 Closed
Susquehanna International Group
191
Susquehanna International Group
Pennsylvania
– -$465K -258 Closed
AG
192
Algert Global
California
– -$466K -249 Closed
EAM
193
Erste Asset Management
Austria
– -$443K -249 Closed
ARTA
194
A.R.T. Advisors
New York
– -$445K -238 Closed
GAM
195
Gotham Asset Management
New York
– -$377K -202 Closed
Jane Street
196
Jane Street
New York
– -$296K -158 Closed
PIM
197
Partner Investment Management
California
– -$204K -109 Closed
SCA
198
Secor Capital Advisors
New York
– -$198K -106 Closed
BCM
199
Bayesian Capital Management
New York
– -$185K -99 Closed
CMBA
200
C.M. Bidwell & Associates
Hawaii
– -$63K -34 Closed
5 6 7
8
9

ACOR Hedge Fund Activity: Q1 2019 in Review

184 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2019, worth a combined $761M — down 7.9% from $826M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 21 closed out — a net gain of 5 holders — while 79 added to existing stakes and 41 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $27.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $17.3M sold.

  • 184 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2019, up from 179 in Q4 2018.
  • Funds reported $761M of Acorda Therapeutics stock for Q1 2019, down 7.9% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q1 2019 and 21 closed out, a net change of +5 holders.
  • The largest Acorda Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $27.4M added.
  • The largest Acorda Therapeutics seller in Q1 2019 was PFM Health Sciences, an estimated $17.3M sold.

Based on aggregated 13F filings for Q1 2019.